Research
Active learning FEP using 3D-QSAR for prioritizing bioisosteres in medicinal chemistry
Throughout the webinar we will explore an advanced active learning workflow for drug discovery, demonstrated through human aldose reductase inhibitors. ...
Ignite 2025: Fast-track your innovation to commercial reality
Are you aiming to pursue your entrepreneurial ambition and get your business idea off the ground this year? Do you need support to make it happen? Get ready to ignite your career, your innovation or new venture in 2025. ...
EnterpriseWOMEN: Apply by 10 Feb 2025
This university-level entrepreneurship learning programme is designed for women in the early-stages of their entrepreneurial journey. Whether you’re exploring entrepreneurship, you’re an early-stage founder, or somewhere in between EnterpriseWOMEN is for you. ...
Enterprise Tuesday: Quantum - Ready or Not
Quantum Computing is set to redefine the limits of what we can achieve. It is predicted to have an impact sooner rather than later and now is the time to think about its impact on your start up or organisation. ...
Milner Institute partners with Flagship Pioneering and CUHP to accelerate biotech research and innovation
The Milner Therapeutics Institute are delighted to announce a new collaboration with Flagship Pioneering and Cambridge University Health Partners (CUHP), to jointly advance breakthrough scientific research and technologies. ...
Research & Innovation 2025
ELRIG Research & Innovation 2025 takes place from 10–11 March at The Royal Society of Medicine in London, UK. The free-to-attend event will bring together scientists, researchers and entrepreneurs from across the drug discovery community working on proteins, RNA, cell and gene thera...
ELRIG announces Drs Jue Wang and Robert Grundy as keynote speakers at Research & Innovation 2025
• ELRIG Research & Innovation 2025 takes place in London, UK from 10–11 March • Event will focus on ‘Big molecules to big data…thinking BIG to drive innovative research’ ...
Glox Therapeutics awarded share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
£500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosisProgramme delivered by CF AMR Syndicate offers cross-sector collaboration and support to address urgent unmet needGlasgow, ...
Rethinking Innovation 2025
Inspiring talks, discussions and networking to advance your thinking on sustainability, innovation and technology management. ...
Milner Therapeutics Institute announces 2025 Consortium Call
The 2025 Milner Therapeutics Consortium Call opened on 13 January, with an exciting new focus around pharma-led challenges. ...